Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial

NCT00138671 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00138671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00138671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2003
Completion date
September 30, 2008
Enrollment
105 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, diabetes mellitus